Streetbeat News

Analyst Ratings

CPNG

Barclays analyst Jiong Shao has maintained an Overweight rating on Coupang (NYSE:CPNG) and raised the price target from $22 to $24.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:36 am

WHD

Barclays analyst David Anderson maintains an Equal-Weight rating on Cactus (NYSE:WHD) and raises the price target from $46 to $48.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:35 am

OCX

OncoCyte (NASDAQ:OCX) reported Q2 losses of $(0.59) per share, beating the analyst consensus estimate of $(0.87) by 32.18 percent. This is a 490 percent decrease over losses from the same period last year. The company also reported quarterly sales of $463.00 thousand, beating the analyst consensus estimate of $360.00 thousand by 28.61 percent, but this is a 77.60 percent decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:34 am

OCEA

Ocean Biomedical Inc (NASDAQ:OCEA) has shared updates on its programs in malaria, fibrosis, and multiple cancers. The company's early preclinical findings show significant tumor growth reduction in brain and lung cancers. It is also advancing its understanding of malaria parasite death mechanisms and developing an mRNA vaccine candidate. In fibrosis research, Ocean's anti-fibrotic treatment candidate, OCF-203, has shown impressive fibrosis reductions. The company's shares are up 3.53% in the premarket session.

Portfolio Pulse from Vandana Singh

August 10, 2023 | 11:30 am

BRBR

Barclays analyst Lauren Lieberman maintains an Overweight rating on BellRing Brands (NYSE:BRBR) and raises the price target from $41 to $43.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:29 am

ARMK

Barclays analyst Manav Patnaik maintains an Underweight rating on Aramark (NYSE:ARMK) and raises the price target from $36 to $38.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:29 am

OLPX

Barclays analyst Lauren Lieberman maintains an Underweight rating on Olaplex Hldgs (NASDAQ:OLPX) and lowers the price target from $3 to $2.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:27 am

JACK

Barclays analyst Jeffrey Bernstein has maintained an Equal-Weight rating on Jack In The Box (NASDAQ:JACK) but lowered the price target from $99 to $90.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:26 am

GRPN

Barclays analyst Trevor Young maintains an Underweight rating on Groupon (NASDAQ:GRPN) and raises the price target from $4 to $6.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:26 am

FATE

Barclays analyst Peter Lawson maintains an Overweight rating on Fate Therapeutics (NASDAQ:FATE) but has lowered the price target from $12 to $6.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:25 am